Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 16,753,388
  • Shares Outstanding, K 536,280
  • Annual Sales, $ 11,077 M
  • Annual Income, $ 480,000 K
  • 36-Month Beta 1.31
  • Price/Sales 1.51
  • Price/Cash Flow 4.11
  • Price/Book 1.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.53 +5.99%
on 08/30/17
33.67 -7.04%
on 09/12/17
+0.57 (+1.85%)
since 08/22/17
3-Month
29.39 +6.50%
on 08/15/17
39.80 -21.36%
on 07/21/17
-7.71 (-19.76%)
since 06/22/17
52-Week
29.39 +6.50%
on 08/15/17
45.87 -31.76%
on 03/01/17
-11.29 (-26.51%)
since 09/22/16

Most Recent Stories

More News
Mylan Down 24% Year to Date: What's Troubling the Stock?

Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.

MYL : 31.30 (+0.19%)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences

If you want a Stock Review on MNK, HZNP, MYL, or NBIX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com have issued research...

MYL : 31.30 (+0.19%)
HZNP : 12.32 (+0.41%)
NBIX : 58.93 (+0.17%)
MNK : 34.83 (-0.09%)
Biosimilar 2017 Progress Report: Stocks in Focus

The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.

MYL : 31.30 (+0.19%)
MRK : 65.13 (-0.72%)
AGN : 204.65 (+0.98%)
NVS : 86.16 (+1.44%)
MNTA : 17.15 (+2.08%)
AMGN : 185.76 (-0.47%)
BIIB : 318.46 (+1.09%)
Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets

Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women...

MYL : 31.30 (+0.19%)
AGN : 204.65 (+0.98%)
Mylan Names Dennis Zeleny as Chief Human Relations Officer

Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Dennis Zeleny as chief human relations officer. Zeleny joins Mylan with 30 years of experience leading global, corporate HR organizations...

MYL : 31.30 (+0.19%)
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump

The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.

MYL : 31.30 (+0.19%)
RDY : 37.66 (-0.16%)
HLUYY : 60.1180 (+2.89%)
TEVA : 17.19 (+0.23%)
Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?

Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).

MYL : 31.30 (+0.19%)
NVO : 49.22 (+0.33%)
MNTA : 17.15 (+2.08%)
TEVA : 17.19 (+0.23%)
Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018

Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.

MYL : 31.30 (+0.19%)
AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
LLY : 83.91 (+0.70%)
NVS : 86.16 (+1.44%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
Key FDA Regulatory Events to Watch Out for in Sep 2017

Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?

PTCT : 18.52 (-7.63%)
MYL : 31.30 (+0.19%)
MRK : 65.13 (-0.72%)
AMGN : 185.76 (-0.47%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
Mylan Nv (MYL) Breaks Through Support at $30.58

Shares of Mylan Nv (NASDAQ:MYL) opened today below their pivot of $30.83 and have already reached the first level of support at $30.58. Analysts will be watching for a cross of the next downside pivot...

MYL : 31.30 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Support & Resistance

2nd Resistance Point 31.91
1st Resistance Point 31.60
Last Price 31.30
1st Support Level 30.84
2nd Support Level 30.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.